Cancer Stem Cells Therapy Market Size - By Type (Targeted Cancer Stem Cells, Stem Cells-based), Cancer Type (Breast, Lung, Colorectal, Prostrate), End-user, Global Forecast (2023- 2032)

Cancer Stem Cells Therapy Market Size

Cancer Stem Cells Therapy Market size was valued at USD 4.4 billion in 2022 and is estimated to account for USD 12 billion by 2032 due to several factors such as the increasing cases of cancer, growing private and public initiatives and rising awareness regarding availability of stem cell therapy.
 

For instance, according to World Health Organization (WHO), cancer was the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Therefore, there is a larger patient population in need of effective treatments. Cancer stem cells therapy refers to targeted treatments and therapeutic strategies specifically designed to identify, target, and eliminate cancer stem cells therapy (CSCs) within tumors. Cancer stem cells therapy are a subset of cells within a tumor that exhibit stem cell-like properties, including the ability to self-renew and differentiate into various cell types found in the tumor. These cells are believed to play a significant role in tumor progression, metastasis, and resistance to conventional cancer therapies.
 

COVID-19 Impact

The market experienced a favourable effect due to the COVID-19 pandemic. During this global health crisis, there was a notable increase in focus on healthcare and biomedical research, with funding agencies and governments allocating additional resources for research, including cancer stem cells therapy. Moreover, the pandemic prompted researchers to adapt and innovate, leading to the emergence of new research strategies and collaborations.
 

Cancer Stem Cells Therapy Market Trends

• The market is experiencing substantial expansion due to several key factors. One of the primary factors is the progressively rising cancer patients globally. For instance, according to the World Cancer Research Fund International, there were an estimated 18.1 million cancer cases globally in 2020.
   

This surge in cancer incidence has generated a heightened demand for more efficacious treatments. Furthermore, cancer stem cells therapy have been identified as key players in tumor recurrence following initial treatments. Therapies that target these specific cells aim to diminish the likelihood of cancer coming back post-surgery, chemotherapy, or radiation therapy.
 

• Conversely, despite the numerous advantages associated with cancer stem cells therapy, a significant challenge and potential obstacle to its widespread adoption. The creation of these therapies necessitates extensive research, preclinical investigations, and clinical trials, all of which not only consume a substantial amount of time but also require significant financial investments.
   
• Furthermore, when tailored to target cancer stem cells therapy, these therapies often involve intricate processes such as cell isolation, genetic modification, and personalized treatment planning.
   

Cancer Stem Cells Therapy Market Analysis

Based on type, the market is segmented into targeted cancer stem cells and stem cells-based therapy. The stem cells-based therapy segment held the largest market size in 2022 with a USD 3.7 billion.

• The dominance of the segment can be attributed to their extensive usage in regenerative medicine, aiming to replace or repair damaged tissues and organs. This broad application has led to significant investments and research efforts.

• Further, stem cells-based therapy has shown promise in the treatment of various types of cancer. As they can differentiate into different cell types, making them valuable for treating conditions. Therefore, the availability & accessibility, potential benefits allows a quicker and smooth approval process for stem cells-based therapy.
   

Based on cancer type, the cancer stem cells therapy market is classified into breast, lung, colorectal, prostrate, stomach, liver, and other cancer types. The breast cancer segment accounted for 24.4% market share in the year 2022.
 

• Breast cancer is one of the most common cancers worldwide, affecting a large number of individuals. For instance, according to the World Health Organization (WHO), in 2020, there were 2.3 million women diagnosed with breast cancer and 6,85,000 deaths globally. This high prevalence and incidence of breast cancer generate a substantial patient population for research and clinical trials, making it a focal point for cancer stem cells therapy.
   
• Moreover, increased funding and public awareness have accelerated research efforts, including studies focused on cancer stem cells therapy for breast cancer therapeutics.
   

Based on end-user, the cancer stem cells therapy market is classified into hospitals, specialty centres, and other end-users. The hospitals segment is expected to reach USD 6.5 billion in 2032.
 

• Hospitals are often the primary sites for conducting clinical trials related to cancer stem cells therapies. Research conducted within hospital settings provides valuable data, contributes to scientific knowledge. Also, the high volume of procedures conducted in hospitals creates a constant and significant demand for the stem cells.
   
• Further, hospitals engage in partnerships with research institutions, pharmaceutical companies, and biotechnology firms to participate in the development and evaluation of cancer stem cells treatments. These collaborative endeavors encourage creative breakthroughs and propel the field forward, with hospitals playing a central role in these initiatives.
   

The North America cancer stem cells therapy market is expected to grow at 10% by 2032.
 

• The region boasts an exceptionally advanced healthcare infrastructure, featuring state-of-the-art hospitals, research institutions, and biotechnology companies well-equipped to conduct cutting-edge research and clinical trials focused on cancer stem cells therapy. Also, it has access to significant venture capital, private equity funding, and investment opportunities. This financial support is expected to fuel the cancer stem cells therapy activities.
   
• The region's contribution to the global cancer stem cells market is underscored by the increasing incidence of cancer cases, particularly in the United States. For instance, in 2022, there were approximately 1.9 million new cancer cases diagnosed in the U.S., with 609,360 cancer-related deaths. This rise in cancer incidence drives the demand for innovative and effective cancer therapies, including those based on cancer stem cells research.
   

Cancer stem cells therapy Market Share

The key players operating in this market have established themselves through, continuous research & development, and a strong market presence. Gamida Cells, AbbVie Inc, and Astellas Pharma Inc account significant market share. These prominent players thrive through a combination of strategic approaches, diverse product portfolio, research and development initiatives, market understanding, and regulatory compliance.
 

Market players operating in the cancer stem cells therapy is as mentioned below:

• Gamida Cells
• AbbVie Inc
• Astellas Pharma Inc
• Novadip Biosciences
• ReNeuron Group plc
• Celyad
• Adna GmBH
• Thermo Fisher Scientific
• Genentech Inc
• Merck KGaA

Cancer stem cells therapy Industry News:

• In August 2023, Astellas Pharma Inc announced a strategic investment in Poseida Therapeutics, Inc. It helped to establish the Focus Area Approach and expanded the research & development of stem cell therapies, including cancer. Thus, it boosted the product portfolio and increased the reach.

• In January 2022, Gamida Cells announced the rolling Biologics License Application (BLA) submission for omidubicel. It is a clinically developed off-the-shelf bone marrow stem cell transplant for patients detected with blood cancers.

The cancer stem cells therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Type, 2018 – 2032 (USD Million)

• Targeted cancer stem cells
• Stem cells-based therapy
  • Allogenic stem cell
  • Autologous stem cell

By Cancer Type, 2018 – 2032 (USD Million)

• Breast
• Lung
• Colorectal
• Prostrate
• Stomach
• Liver
• Other cancer types

By End-user, 2018-2032 (USD Million)

• Hospitals
• Specialty centres
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa